SAN DIEGO (GenomeWeb News) — Reporting incidental or secondary findings may pose a challenge for the cancer field, a panel at this year's American Association for Cancer Research meeting said.

The panelists particularly focused their discussion on recommendations the American College of Medical Genetics and Genomics issued last year and updated about a week ago. Those guidelines list a set of some 56 genes for which variants should be reported back to patients undergoing clinical sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.